Chemists from the Faculty of Science and Technology at the University of Silesia have developed a substance showing several times better effectiveness in the treatment of colon cancer than imatinib, which was used so far. The authors of the patented invention are Dr Eng. Jacek Mularski, Dr Katarzyna Malarz and Prof. Robert Musioł.

The developed styrylquinazolinone derivative may be particularly useful in oncological patients with damage to the p53 protein. This protein is called the genome guardian. It is responsible, for activating the repair mechanisms of DNA damaged by disease.

Treatment of patients with diagnosed cancers who develop such damage is much more difficult and is often associated with a worse prognosis. That is why it is so important to search for new chemical compounds that can positively affect the course of therapy. The new styrylquinazolinone derivative brings such new hopes.